


# PRODUCT INFORMATION



## Trequinsin (hydrochloride)

Item No. 17217

**CAS Registry No.:** 78416-81-6  
**Formal Name:** 2,3,6,7-tetrahydro-9,10-dimethoxy-3-methyl-2-[(2,4,6-trimethylphenyl)imino]-4H-pyrimido[6,1-a]isoquinolin-4-one, monohydrochloride  
**MF:**  $C_{24}H_{27}N_3O_3 \cdot HCl$   
**FW:** 442.0  
**Purity:**  $\geq 98\%$   
**Supplied as:** A solid  
**Storage:**  $-20^{\circ}C$   
**Stability:**  $\geq 4$  years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

### Laboratory Procedures

Trequinsin (hydrochloride) is supplied as a solid. A stock solution may be made by dissolving the trequinsin (hydrochloride) in the solvent of choice. Trequinsin (hydrochloride) is soluble in organic solvents such as ethanol and DMSO, which should be purged with an inert gas. The solubility of trequinsin (hydrochloride) in these solvents is approximately 100 mM.

### Description

Trequinsin is a phosphodiesterase (PDE) 3 inhibitor that is dependent on cyclic AMP (cAMP), with  $IC_{50}$  values of 0.04 and 0.03 nM for PDE3A and PDE3B, respectively, in T84 human colonic adenocarcinoma cell lysates.<sup>1</sup> In cultured primary rat juxtaglomerular cells, trequinsin stimulates cAMP accumulation when used at a concentration of 10  $\mu M$  and increases cell membrane capacitance in a patch clamp assay.<sup>2</sup> Trequinsin also competitively inhibits the multidrug resistant protein 5-mediated export of cGMP from Chinese hamster lung fibroblasts with a  $K_i$  value of 240 nM.<sup>3</sup> *In vivo*, trequinsin reduces collagen-induced platelet aggregation in rabbits when administered intravenously at a rate of 3  $\mu g/kg$  per minute, as well as the collagen-induced decrease in mean arterial blood pressure when administered alone or in combination with prostacyclin.<sup>4</sup>

### References

1. Liu, S., Veilleux, A., Zhang, L., *et al.* Dynamic activation of cystic fibrosis transmembrane conductance regulator by type 3 and type 4D phosphodiesterase inhibitors. *J. Pharmacol. Exp. Ther.* **314**(2), 846-854 (2005).
2. Friis, U.G., Jensen, B.L., Sethi, S., *et al.* Control of renin secretion from rat juxtaglomerular cells by cAMP-specific phosphodiesterases. *Circ. Res.* **90**(9), 996-1003 (2002).
3. Jedlitschky, G., Burchell, B., and Keppler, D. The multidrug resistance protein 5 functions as an ATP-dependent export pump for cyclic nucleotides. *J. Biol. Chem.* **275**(39), 30069-30074 (2000).
4. Darius, H., Lefer, A.M., Leprán, I., *et al.* *In vivo* interaction of prostacyclin with an inhibitor of cyclic nucleotide phosphodiesterase, HL 725. *Br. J. Pharmacol.* **84**(3), 735-741 (1985).

#### WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

#### SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

#### WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 11/15/2022

#### CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD  
ANN ARBOR, MI 48108 · USA

**PHONE:** [800] 364-9897  
[734] 971-3335

**FAX:** [734] 971-3640

CUSTSERV@CAYMANCHEM.COM  
WWW.CAYMANCHEM.COM